Epimedium-derived flavonoids promote osteoblastogenesis and suppress adipogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone

Bone

Volumn 45, Issue 3, 2009, Pages 534-544

  Songlin, Peng ^a,b   Ge, Zhang ^a   Yixin, He ^a   Xinluan, Wang ^a   Pingchung, Leung ^a   Kwoksui, Leung ^a   Ling, Qin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anabolic effect; Histomorphometry; Osteoporosis; Phytoestrogen; Stem cell

Indexed keywords

ALKALINE PHOSPHATASE; BAOHUOSIDE I; BINDING PROTEIN; EPIMEDOSIDE A; EPIMENDIN A; EPIMENDIN B; EPIMENDIN C; FLAVONOID; HEXANDRASIDE F; ICARIIN; NATURAL PRODUCT; OSTEOCALCIN; PROTEIN TRACP 5B; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MARROW CELL; BONE TURNOVER; CELL DIFFERENTIATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; EPIMEDIUM; FEMALE; FEMUR; GENE EXPRESSION; HUMAN; HUMAN CELL; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; STROMA CELL;

ADIPOGENESIS; ANABOLIC AGENTS; ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; EPIMEDIUM; FEMALE; FLAVONOIDS; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, WISTAR; STROMAL CELLS;

EID: 67949098855     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.05.022     Document Type: Article

References (49)

1. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflict, and prospects. J. Clin. Invest. 115 (2005) 3318-3325
2. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997) 71-74
3. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
4. Meunier P., Aaron J., Edouard C., and Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin. Orthop. 80 (1971) 147-154
5. Burkhardt R., Kettner G., Bohm W., Schmidmeier M., Schlag R., Frisch B., et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 8 (1987) 157-164
6. Verma S., Rajaratnam J.H., Denton J., Hoyland J.A., and Byers R.J. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Clin. Pathol. 55 (2002) 693-698
7. Rodríguez J.P., Garat S., Gajardo H., Pino A.M., and Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J. Cell. Biochem. 75 (1999) 414-423
8. Sekiya I., Larson B.L., Vuoristo J.T., Cui J.G., and Prockop D.J. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J. Bone Miner. Res. 19 (2004) 256-264
9. Beresford J.N., Bennett J.H., Devlin C., Leboy P.S., and Owen M.E. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J. Cell. Sci. 102 (1992) 341-351
10. Rodríguez J.P., Montecinos L., Ríos S., Reyes P., and Martínez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J. Cell. Biochem. 79 (2000) 557-565
11. Mukherjee S., Raje N., Schoonmaker J.A., Liu J.C., Hideshima T., Wein M.N., et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118 (2008) 491-504
12. Yamaza T., Miura Y., Bi Y., Liu Y., Akiyama K., Sonoyama W., et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 3 (2008) e2615
13. Elabd C., Basillais A., Beaupied H., Breuil V., Wagner N., Scheideler M., et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells 26 (2008) 2399-2407
14. Lee S.H., Jung B.H., Kim S.Y., and Chung B.C. Determination of phytoestrogens in traditional medicinal herbs using gas chromatography-mass spectrometry. J. Nutr. Biochem. 15 (2004) 452-460
15. Qin L., Zhang G., Shi Y., Lee K.M., and Leung P.C. Prevention and treatment of osteoporosis with traditional herbal medicine. In: Deng H.W., Liu Y.Z., Guo C.Y., and Chen D. (Eds). Current topics of osteoporosis (2005), World Scientific Publisher, Singapore 513-531
16. Zhang G., Qin L., and Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J. Bone Miner. Res. 22 (2007) 1072-1079
17. Zhang G., Qin L., Hung W.Y., Shi Y.Y., Leung P.C., Yeung H.Y., et al. Flavonoids derived from herbal Epimedium brevicornum Maxim prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. Bone 38 (2006) 818-825
18. Shiraishi A., Higashi S., Masaki T., Saito M., Ito M., Ikeda S., et al. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif. Tissue Int. 71 (2002) 69-79
19. Recker R.R., Weinstein R.S., Chesnut III C.H., Schimmer R.C., Mahoney P., Hughes C., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos. Int. 15 (2004) 231-237
20. Ciria-Recasens M., Perez-Edo L., Blanch-Rubio J., Marinoso M.L., Benito-Ruiz P., Serrano S., et al. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone 36 (2005) 926-930
21. Heim M., Frank O., Kampmann G., Sochocky N., Pennimpede T., Fuchs P., et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 145 (2004) 848-859
22. Dang Z., and Löwik C.W. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J. Bone Miner. Res. 19 (2004) 853-861
23. Chen K.M., Ma H.P., Ge B.F., Liu X.Y., Ma L.P., Bai M.H., et al. Icariin enhances the osteogenic differentiation of bone marrow stromal cells but has no effects on the differentiation of newborn calvarial osteoblasts of rats. Pharmazie 62 (2007) 785-789
24. Lai Y.M., Qin L., Hung V.W.Y., and Chan K.M. Regional differences in cortical bone mineral density in weight-bearing long bone shaft-a pQCT study. Bone 36 (2005) 465-471
25. Kimmel D.B. Animal models for in vivo experimentation in osteoporosis research. In: Marcus R., Feldman D., and Kelesy J. (Eds). Osteoporosis (1996), Academic Press, San Diego 671-690
26. Siu W.S., Qin L., Cheung W.H., and Leung K.S. A study of trabecular bones in ovariectomized goats with micro-computed tomography and peripheral quantitative computed tomography. Bone 35 (2004) 21-26
27. Gong H., Zhang M., Yeung H.Y., and Qin L. Regional variations in microstructural properties of vertebral trabeculae with aging. J. Bone Miner. Metab. 23 (2005) 174-180
28. Parfitt A.M. Bone histomorphometry: standardization of nomenclature, symbols and units. Summary of proposed system. Bone Miner. 4 (1988) 1-5
29. Bianco P., and Gehron Robey P. Marrow stromal stem cells. J. Clin. Invest. 105 (2000) 1663-1668
30. Lane N.E., Yao W., Kinney J.H., Modin G., Balooch M., and Wronski T.J. Both hPTH (1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J. Bone Miner. Res. 18 (2003) 2105-2115
31. Sampath T.K., Simic P., Moreno S., Bukanov N., Draca N., Kufner V., et al. Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. Endocrinology 149 (2008) 6092-6102
32. Luu Y., Capilla E., Rosen C., Gilsanz V., Pessin J., Judex S., et al. Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary induced obesity. J. Bone Miner. Res. 24 (2009) 50-61
33. Hirano T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14 (1999) 536-545
34. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., and Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16 (2001) 157-165
35. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
36. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 (2002) 653-661
37. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al., AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22 (2007) 1832-1841
38. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas M.G., Ellis-Pegler R.B., et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J. Bone Miner. Res. 23 (2008) 1304-1308
39. Gasser J.A., Ingold P., Venturiere A., Shen V., and Green J.R. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J. Bone Miner. Res. 23 (2008) 544-551
40. Marie P.J., Hott M., Modrowski D., De Pollak C., Guillemain J., Deloffre P., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. 8 (1993) 607-615
41. Choudhary S., Halbout P., Alander C., Raisz L., and Pilbeam C. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J. Bone Miner. Res. 22 (2007) 1002-1010
42. Bonnelye E., Chabadel A., Saltel F., and Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42 (2008) 129-138
43. Bergman R.J., Gazit D., Kahn A.J., Gruber H., McDougall S., and Hahn T.J. Age-related changes in osteogenic stem cells in mice. J. Bone Miner. Res. 11 (1996) 568-577
44. Tokalov S.V., Grüner S., Schindler S., Wolf G., Baumann M., and Abolmaali N. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev. 16 (2007) 439-446
45. Ducy P., Zhang R., Geoffroy V., Ridall A.L., and Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 (1997) 747-754
46. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
47. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 (2004) 1701-1712
48. Steiniche T., Hasling C., Charles P., Eriksen E.F., Mosekilde L., and Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10 (1989) 313-320
49. Bakker A.D., Klein-Nulend J., Tanck E., Albers G.H., Lips P., and Burger E.H. Additive effects of estrogen and mechanical stress on nitric oxide and prostaglandin E2 production by bone cells from osteoporotic donors. Osteoporos. Int. 16 (2005) 983-989